TPS1613 Background: Long term follow up of cancer survivors uncovers iatrogenic risk. Higher risk for second cancers should be mainly observed for cancer with a high rate of therapeutic efficacy, using aggressive therapeutic and for cancers occurring in young people. Hodgkin lymphoma fits all these criteria. Consistent data about higher risk for breast cancer in these women had been published. However, risk management is not yet often carried out. Methods: We plan to carry out a national program aiming both at offering counselling and screening protocol and to assess key parameters allowing to better estimate risk, and offering acceptable and effective risk management option. Our National program will start in January 2013. We are now in a pilot phase in a single medical institution in which we offered women previously affected with an Hodgkin lymphoma to have access to risk analysis and information and if they agree to a specific breast cancer screening program. We present some of our psychosocial questionnaire analysis based on 27 women (aged 19-50 years old) fulfilled at the end of the information consultation and one month latter. Results: There was few or no negative assessment: no one stated that they express regrets to have been informed, nor they better ignore some delivered information, no one feel that risk management description is unsatisfying and no one will advice an other women against that kind of consultation. Only 4 out 27 i.e. 15% stated that there was in delivered information a source for anxiety. However positive assessment was only fairly high and not stable after one month. Information process to inform women survivors from Hodgkin lymphoma of their higher risk of being affected with a breast cancer and the current recommendation for earlier breast cancer screening reach a high level of satisfaction at the initial stage of the process. However it could decrease with time and thus, need to be monitored. [Table: see text]
A limited review of over diagnosis methods and long-term effects in breast cancer screening
